MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Coherus Oncology Inc

Suletud

SektorTervishoid

1.75 2.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.68

Max

1.77

Põhinäitajad

By Trading Economics

Sissetulek

354M

298M

Müük

2.7M

10M

P/E

Sektori keskmine

2.833

35.739

Kasumimarginaal

2,903.911

Töötajad

177

EBITDA

-1.3M

-45M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+135.67% upside

Turustatistika

By TradingEconomics

Turukapital

97M

198M

Eelmine avamishind

-1.19

Eelmine sulgemishind

1.75

Uudiste sentiment

By Acuity

50%

50%

183 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2025, 16:58 UTC

Tulu

BMW Trims 2025 View, Citing Weaker Performance in China

7. okt 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. okt 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. okt 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. okt 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. okt 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 20:44 UTC

Kuumad aktsiad

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. okt 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. okt 2025, 19:23 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. okt 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. okt 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. okt 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. okt 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. okt 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. okt 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. okt 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. okt 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. okt 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. okt 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. okt 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. okt 2025, 14:52 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

135.67% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD  135.67%

Kõrge 7 USD

Madal 1.1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

183 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat